Albert Lowe
Stock Analyst at Craig-Hallum
(1.98)
# 2,988
Out of 4,883 analysts
9
Total ratings
44.44%
Success rate
6.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Initiates: Buy | $50 | $19.50 | +156.41% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $4 | $0.85 | +372.93% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $0.99 | +504.78% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $4.39 | +218.91% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $1.96 | +461.22% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $3.65 | +119.18% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $0.95 | +320.88% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.20 | +400.00% | 1 | May 13, 2024 |
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $19.50
Upside: +156.41%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $4
Current: $0.85
Upside: +372.93%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $0.99
Upside: +504.78%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $4.39
Upside: +218.91%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $1.96
Upside: +461.22%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $3.65
Upside: +119.18%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $0.95
Upside: +320.88%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.20
Upside: +400.00%